Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advanced BioScience Laboratories (ABL) has received a contract from the NIH National Institute of Allergy and Infectious Diseases (NIAID) to provide preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.
Subscribe to our email newsletter
Under the $102m contract, titled as "Manufacture and Characterization Services (MCS) for Vaccines and Other Biologics for Infectious Diseases", ABL will provide services from early feasibility studies through manufacture of Phase I/II material to more rapidly and efficiently close development and production gaps and increase the government’s response to emerging disease threats.
ABL will also provide appropriate documentation and support for regulatory submissions for Phase I and II clinical testing.
ABL president and CEO Thomas VanCott said ABL is excited at the prospect of applying novel approaches, platforms and technologies in support of NIAID’s mission to develop candidates against a wide range of infectious diseases.
”This will be a great opportunity for ABL to develop vaccines and therapies targeting some of the most challenging agents including potential bioterror threats, drug-resistant pathogens, and emerging and re-emerging infectious diseases, " VanCott added.
The contract, which is spread over 10 years, has been funded with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN272201200005I.